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Background: Prolongation of waiting-times for heart transplantation (HTx) increases the need for new therapies for heart failure. In short-
term follow-up studies, immunoadsorbtion (IA) showed promising results in patients with dilated cardiomyopathy (DCM) associated with `1-
adrenoreceptor autoantibodies (`1-AABs). We assessed the responsiveness to IA, its long-term therapeutic efficacy and the impact of selectivity of 
`1-AAB removal on IA results in HTx candidates with DCM.
Methods: Cardiac function and patient survival without HTx or ventricular assist devices (VADs) were evaluated in `1-AAB positive HTx candidates 
with DCM who underwent IA between 1995 − 2005 (follow-up: 5 − 14.5 years). We also looked for differences in efficacy between unselective 
(unspecific IA) and selective (specific IA) `1-AAB removal and for differences in IA results between patients with high and low `1-AAB levels.
Results: In 131 patients with high `1-AAB levels (≥ 3LU), unspecific and specific IA showed the same high efficiency in `1-AAB removal. LVEF and 
NYHA class improved (p < 0.01) after both, but there were no differences in post-IA LVEF or NYHA class improvement between patients with specific 
and unspecific IA. Kaplan-Meier estimates revealed probabilities for 5 year HTx/VAD-free survival of 83.1 ± 8.6% for unspecific and 91.3 ± 5.9% for 
specific IA. The prevalence of responders to specific and unspecific IA was similar (78.3% and 79.6%, respectively). Post-IA `1-AABs reappearance 
coincided with cardiac worsening. There were no differences in cardiac function, patient outcome and adverse side effects between patients who 
underwent unspecific IA using peptides or native proteins as ligands. In comparison to patients with high`1-AAB levels, a smaller (n = 19) DCM 
patient “control group” with low `1-AAB levels (< 3LU) showed little benefit from IA.
Conclusions: Removal of ß1-AABs by specific or unspecific IA improves cardiac function and allows long-term cardiac stability in end-stage DCM 
which can spare many patients from HTx or will delay HTx listing for many years. Our data suggest that in`1-AAB positive DCM patients the benefits 
of both specific and unspecific IA are related to the removal of these antibodies.
